ASCO 2022: Breast cancer highlights

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC